The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted ...
GMO’s seven-year asset-class forecasts are known for reflecting contrarian views that rely on valuations reverting to long-run averages. Using these forecasts as a compass and tempering them ...